WASHINGTON DC—Doctors taking the unusual step of combining two experimental drugs to treat cancers in patients who have mutated BRCA — the gene conferring susceptibility to breast, ovarian and some other solid tumours — found that patients responded through what appears to be a synergistic action. Dr Geoffrey Shapiro, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute in Boston presented findings at the American Association for Cancer Research Annual Meeting on the combination of sapacitabine (a nucleoside analogue) and seleciclib (a cyclin-dependent kinase inhibitor). He discussed the clinical potential of this technique with Peter Goodwin.
You may also like...
Blood test reliably detects cancer mutations in gastrointestinal stromal tumour 24 Apr, 2013 BCL-2: A New Therapeutic Target in Estrogen-Receptor Positive Breast Cancer 27 Mar, 2015 Which patients for bisphosphonate control of breast cancer metastasis? 29 Mar, 2013 Virus Plus Cytokine Fight Primary and Metastatic Cancer 15 Aug, 2007
- Previous story Treatment “holidays” to overcome resistance in advanced melanoma?
- Next story Breast cancer chemoprevention: meta-analysis shows SERMs are highly effective
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014